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Systematic development of combination chemotherapies has
signiﬁcantly improved the prognosis of acute lymphoblastic
leukemia (ALL). Patients with T-cell ALL (T-ALL) still have less
favorable outcomes, and the prognosis of relapsed T-ALL is
dismal.1 In order to ﬁnd novel targeted therapies for T-ALL, we
retrieved the gene expression proﬁles of 4430 leukemia samples
from the Gene Expression Omnibus (GEO) and performed an in
silico drug target screening, where the expression proﬁles were
compared with known drug targets in the Drug signature
database (DsigDB).2,3 This compound library contains both FDA
(Food and Drug Administration) – approved and novel investiga-
tional drugs. Strong expression of Src family tyrosine kinase LCK
was detected in T-ALL samples, exceeding that of other leukemias
and normal T cells (Figure 1a), whereas a LCK-targeting drug,
dasatinib, decreased the kinase activity of LCK to 1% in
comparison with the control at a 100 nM concentration.4 Dasatinib
is known to have multiple intracellular targets, and we noticed
that some of them had a similarly elevated expression in T-ALL
patients (Figure 1b and Supplementary Figure S1). Therefore, our
combinatorial drug/target screening suggests dasatinib as a
candidate targeted therapy for T-ALL patients.
To experimentally evaluate the potency of dasatinib, we treated
T-ALL cell lines with increasing concentrations of dasatinib (1–
1000 nM). After 72 h, the most signiﬁcant response was seen in
Figure 1. The in silico and in vitro results indicate dasatinib as a potential drug for T-ALL with LCK as its prime target. (a) LCK expression in
different hematological sample groups: acute leukemia (n= 4430), pre-B-ALL (n= 1304), T-ALL (n= 385) and T lymphoids (n= 247). (b) The
ﬁltered list of targets of dasatinib from in silico screening. The list contains targets with a lower expression in normal cells (myeloid, B lymphoid
and T lymphoid) in comparison with their leukemic counterparts; a signiﬁcant expression difference between T-ALL and T-lymphoid samples
(adjusted Po0.001 and a41.25-fold change) and dasatinib is capable of inhibiting them with high efﬁciency. Percentage of control (POC) or
Kd values were used to estimate the efﬁcacy of dasatinib against its targets. The POC value indicates the percentage of remaining activity after
inhibitor treatment in comparison with the untreated control sample. In addition to 0.5 μM, POC values at 100 nM concentrations were also
available for LCK and ABL1, and they were 1 and 0, respectively. (c) Effect of dasatinib for cell viability in several T-ALL cell lines measured by
alamarBlue assay after 72 h of incubation in 10-fold dasatinib dilution series (1–1000 nM). Values are relative cell viabilites in comparison with
dimethyl sulfoxide (DMSO) control and results are median values from three independent experiments performed in triplicate, except for
CCRF-CEM and HPB-ALL that are from two independent experiments. (d) The expression of 21 potential dasatinib targets in Jurkat cells. Bars
indicate median values. (e) The effect of LCK knockdown for Jurkat cell proliferation measured in time series (0h, 24h, 48 and 72 h) with
alamarBlue assay. Proliferation trend lines are drawn through median values. At time point 72 h, the proliferation had decreased by 14% in
comparison with the mock-treated control (P= 0.0289, Mann–Whitney U-test). The data consist of seven individual experiments performed in
triplicate, and each time point is normalized to the 0 h time point. RT-qPCR and western blot results show the efﬁciency of LCK knockdown.
(f) The effect of dasatinib on cell viability in the LCK-deﬁcient Jurkat cell line in comparison with the normal Jurkat cell line measured by
alamarBlue assay after 72 h of incubation in a 10-fold dasatinib dilution series (1–1000 nM). The difference between the two cell lines was
statistically signiﬁcant already at a 10 nM concentration (P= 0.014, Mann–Whitney U-test). The values are relative cell viabilities in comparison
with the DMSO control, and the results are the median values from three independent experiments performed in triplicate. The error bars
indicate 95% conﬁdence intervals.
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Jurkat cells, with a 31% viability decrease at a 10 nM concentration
(n= 3, P= 0.0039; Figure 1c and Supplementary Figure S2). As
dasatinib inhibits several kinases that are key regulators of cellular
proliferation and viability, we chose a panel of likely candidates (9
targets based on the in silico screening and 12 other well-known
targets from the literature), and analyzed their expression in T-ALL
cell lines by quantitative reverse transcriptase-PCR (RT-qPCR) and
western blotting. LCK was the most prominently expressed gene
in T-ALL cell lines, whereas FYN, ABL1, MAP2K5, MAP4K5 and LYN
were expressed at lower levels (Figure 1d and Supplementary
Figure S3). Knockdown of LCK in a dasatinib-sensitive cell line
(Jurkat) signiﬁcantly decreased cell proliferation (14% decrease,
P= 0.0289, n= 7, Figure 1e), whereas knockdown of FYN, ABL1,
MAP2K5 and MAP4K5 had no signiﬁcant effect (Supplementary
Figures S4a–d). Importantly, Jurkat cells with reduced LCK activity
due to a deletion of exon 7 (cell line J.CaM1.6) lost dasatinib
sensitivity (Figure 1f). Moreover, LCK knockdown did not cause
statistically signiﬁcant decrease of proliferation in relatively
dasatinib-insensitive P12-Ichikawa cell line (Supplementary
Figure S4e). These results suggest that LCK is the prime target
of dasatinib in T-ALL.
We next performed ex vivo drug testing of 22 primary T-ALL
samples. In 6 cases (27%), the response to dasatinib was
signiﬁcant based on drug sensitivity scores (DSS, using a cutoff
value of 10, Figure 2a).5 Half-maximal growth inhibition concen-
trations (IC50) ranged between 1.3 and 16 nM, whereas the control
samples had an IC50 of 41000 nM (Supplementary Figure S5). We
also noted a negative correlation between dasatinib and
glucocorticoid DSS scores (Supplementary Figure S6). Previously,
dasatinib sensitivity has been reported in T-ALL cases with
NUP214-ABL1 fusion.6–8 In contrast, none of the dasatinib
responders in our sample set carried the fusion gene based on
either genomic PCR or RNA-sequencing analysis (Supplementary
Figure S7). LCK was strongly expressed in four out of the ﬁve
dasatinib-responsive patient samples, whereas the expression of
other potential targets varied from a low (LYN, ABL1) to medium
level (FYN, MAP2K5 and MAP4K5, Supplementary Figure S8a). As
LCK was also relatively strongly expressed in dasatinib-insensitive
patient samples, no correlation between dasatinib response and
LCK expression was observed (Supplementary Figure S8b).
As T-ALL subgroups can be separated by expression of speciﬁc
transcription factors, we explored whether dasatinib sensitivity
was associated with any speciﬁc subgroups.9 In addition to Jurkat
cells that belong to the TAL1 subgroup, ﬁve out of six dasatinib-
sensitive patient samples showed either prominent TAL1 expres-
sion (Figure 2b) or carried SIL-TAL1 fusion (data not shown). There
was also increased expression of LMO2 and HOXA9/10 genes in
some samples (Supplementary Figure S9). 6q deletions have also
Figure 2. Dasatinib-sensitive subgroup of T-ALL samples. (a) Drug sensitivity scores (DSS) of dasatinib in a cohort of 22 patient samples. These
DSS values are calculated from growth inhibition measurements after 72 h of treatment in a 10-fold dasatinib dilution series (0.1–1000 nM),
and a DSS value of 10 was used as the threshold for dasatinib sensitivity. (b) The expression of the T-ALL subtype deﬁning transcription factor
TAL1 in T-ALL patient samples and cell lines measured by RT-qPCR. The threshold for ectopic TAL1 expression (dashed line) is deﬁned by the
expression of TAL1 in SIL-TAL1 fusion-positive cell lines, indicated with black columns, and the striped columns represent the dasatinib-
sensitive samples.17 Patient sample 4 was processed in a separate RT-qPCR batch. (c) The heat map of LCK, FYN, MAP2K5, MAP4K5, ABL1 and LYN
expression in a separate GEO-based T-ALL sample data set (n= 385). Samples are clustered based on the expression of T-ALL subtype-deﬁning
transcription factors: TAL1 (n= 61+103), NKX2-1 (n= 18), TLX1 (n= 33), TLX3 (n= 51), HOXA (n= 56) and LYL (n= 63). (d) LCK expression in T-ALL
subtype clusters. The difference between TAL1 clusters and any other cluster was statistically signiﬁcant (Po0.001, Mann–Whitney U-test).
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been associated with the TAL1 subgroup, and three out of six
samples carried the 6q deletion in cytogenetic analyses
(Supplementary Table S1).9 When LCK expression was correlated
with the subgroup information in our GEO-based gene expression
data set, a statistically signiﬁcant correlation was found between
LCK expression and the TAL1 subgroup (Figures 2c and d and
Supplementary Figure S10). However, no direct transcriptional
regulation of LCK by TAL1 was seen when the expression of TAL1
was knocked down (Supplementary Figure S11, data reproduced
from Sanda et al.10).
Taken together, the combination of in silico, in vitro and ex vivo
data indicate that dasatinib exerts clinical utility beyond the
originally suggested NUP214-ABL1 cases that only represent 4–
10% of T-ALL patients.6,11 Our results are in line with the data by
Frismantas et al.12 who identiﬁed a slightly higher percentage of
dasatinib-sensitive patients (30–40%) in their T-ALL cohorts. In
addition to conﬁrming their main ﬁndings, we expand on them in
two different ways. First, we identiﬁed LCK tyrosine kinase as the
potential prime target of dasatinib, whereas Frismantas et al.12 did
not recognize any recurrent gene fusions, mutations or transcrip-
tome proﬁles associated with dasatinib sensitivity; rather, they
associated SRC expression and phosphorylation status with
dasatinib sensitivity. They supported their hypothesis by reporting
a positive correlation between dasatinib and SRC inhibitor KX2-
391 responses in T-ALL patient samples.12 However, DsigDB
identiﬁes both SRC and LCK as targets of KX2-391. In our GEO-
based gene expression data set and T-ALL cell lines, the
expression of SRC was very low when compared with LCK, and
there was no difference in the expression levels of T-ALL and
normal T-cell samples (Supplementary Figure S1). A low level of
SRC expression was also observed in the data set of Frismantas
et al.12 Importantly, the LCK-mutant derivative of the Jurkat cell
line failed to respond to dasatinib, thus strongly suggesting the
central role played by LCK itself. We failed to detect an association
between the phosphorylation status of LCK kinase and dasatinib
sensitivity in T-ALL cell lines (data not shown).
Second, we show here that patients belonging to the TAL1
subgroup are the most likely to respond to dasatinib, although not
exclusively. A high expression of LCK associates with the TAL1
subgroup, but TAL1 does not directly regulate LCK expression. As
up to 60% of T-ALL patients belong to the TAL1 subgroup and
only 30–40% respond to dasatinib, there is clearly a need for more
accurate biomarkers to be identiﬁed.
Dasatinib is known to suppress proliferation of healthy T cells
by LCK inhibition.13–15 We noticed a signiﬁcantly higher
expression of LCK in T-ALL samples compared with healthy
T cells (a 1.46-fold change, Po0.001), and a higher sensitivity of
T-ALL cells toward dasatinib compared with healthy bone
marrow cells. Although we identiﬁed LCK as the main target
of dasatinib, our results do not exclude the contribution by
other kinases, including other Src family kinases. Many of the
target candidates function in receptor signaling pathways
related to cell proliferation and survival. LCK and FYN are
components of the T-cell receptor (TCR) signaling cascade.16
During T-cell development, LCK is required for the normal
development of thymocytes, whereas in mature T cells, FYN is
capable of activating several TCR signaling pathways in the
absence of LCK, including the Ras/extracellular signal-regulated
kinase and phosphatidylinositol 3-kinase pathways.16 In knock-
down experiments, we observed reciprocal feedback mechan-
isms between LCK and FYN (data not shown), in agreement with
their known partially overlapping functions.
Dasatinib is a tyrosine kinase inhibitor that is currently approved
for imatinib-resistant Philadelphia chromosome-positive (Ph+)
chronic myeloid leukemia and the second-line treatment of Ph+
ALL. We report here the potential utility of dasatinib in the
treatment of a subset of T-ALL. As our patient cohort is relatively
small, further studies are needed to explore the biomarker
ﬁndings and to deepen the mechanistic basis before embarking
on animal and human studies.
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